Skip to Main Content

Author Details

Viswanath Devanarayan
Clinical Evidence Generation, Eisai Inc.
1999
61
30
PMIDPaper TitleJournal TitlePublished Year
38087949Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimers Dement2024
38087949Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimers Dement2024
36368195CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework.Neurobiol Aging2023
36368195CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework.Neurobiol Aging2023
37990696Improving the Robustness of Variable Selection and Predictive Performance of Regularized Generalized Linear Models and Cox Proportional Hazard Models.Mathematics (Basel)2023
38057937The age-specific comorbidity burden of mild cognitive impairment: a US claims database study.Alzheimers Res Ther2023
38057937The age-specific comorbidity burden of mild cognitive impairment: a US claims database study.Alzheimers Res Ther2023
37990696Improving the Robustness of Variable Selection and Predictive Performance of Regularized Generalized Linear Models and Cox Proportional Hazard Models.Mathematics (Basel)2023
36053782Predictive signature development based on maximizing the area between receiver operating characteristic curves.Stat Med2022
35821280Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.AAPS J2022
36053782Predictive signature development based on maximizing the area between receiver operating characteristic curves.Stat Med2022
35821280Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.AAPS J2022
34630060Reported Hearing Loss in Alzheimer's Disease Is Associated With Loss of Brainstem and Cerebellar Volume.Front Hum Neurosci2021
33523012Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment.J Alzheimers Dis2021
34630060Reported Hearing Loss in Alzheimer's Disease Is Associated With Loss of Brainstem and Cerebellar Volume.Front Hum Neurosci2021
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
34853961Anti-drug Antibody Validation Testing and Reporting Harmonization.AAPS J2021
33523012Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment.J Alzheimers Dis2021
34853961Anti-drug Antibody Validation Testing and Reporting Harmonization.AAPS J2021
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
33260532Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles.Cells2020
33260532Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles.Cells2020
33025311Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?AAPS J2020
33025311Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?AAPS J2020
30993501Report on the AAPS Immunogenicity Guidance Forum.AAPS J2019
31792633Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.AAPS J2019
30775985Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework.J Alzheimers Dis2019
30993501Report on the AAPS Immunogenicity Guidance Forum.AAPS J2019
31305322VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD.Alzheimer Dis Assoc Disord2019
31792633Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.AAPS J2019
31305322VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD.Alzheimer Dis Assoc Disord2019
30775985Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework.J Alzheimers Dis2019
29345496Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.Bioanalysis2018
29877628Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.Clin Transl Sci2018
29345496Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.Bioanalysis2018
29551332Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the quantitative nature of neurodegenerative disease therapy.Alzheimers Dement2018
29877628Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.Clin Transl Sci2018
29551332Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the quantitative nature of neurodegenerative disease therapy.Alzheimers Dement2018
28733862Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.AAPS J2017
28771542A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.PLoS One2017
28733862Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.AAPS J2017
28147447Patient subgroup identification for clinical drug development.Stat Med2017
28147447Patient subgroup identification for clinical drug development.Stat Med2017
28771542A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.PLoS One2017
26123229Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies.Vet Pathol2016
27238630Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.Alzheimers Dement2016
26123229Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies.Vet Pathol2016
26377333Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.AAPS J2016
26377333Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.AAPS J2016
27238630Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.Alzheimers Dement2016
  • 1 - 50 of 122

Recommended Authors

Martin Goros
University of Texas Health San Antonio
Career Start Year 2013
Number of shared co-authors 0
Jessica Minnier
Louis Stokes Cleveland VA Medical Center Cleveland
Career Start Year 2010
Number of shared co-authors 2
Nicholas P Tatonetti
Columbia Universtiy College of Physicians and Surgeons
Career Start Year 2009
Number of shared co-authors 4
Yunfeng Dai
Colleges of Medicine, University of Florida
Career Start Year 2009
Number of shared co-authors 0
Ioannis Prassas
Mount Sinai Hospital
Career Start Year 2007
Number of shared co-authors 0
Yejin Kim
University of Texas Health Science Center at Houston
Career Start Year 2006
Number of shared co-authors 0
Joel T Dudley
Institute for Next Generation Healthcare
Career Start Year 2006
Number of shared co-authors 4
Mengling Liu
NYU Grossman School of Medicine
Career Start Year 2005
Number of shared co-authors 1
Minya Pu
University of California
Career Start Year 2003
Number of shared co-authors 0
Tapio Pahikkala
University of Turku
Career Start Year 2003
Number of shared co-authors 0
Assaf Gottlieb
Center for Precision Health, University of Texas Health Science Center at Houston
Career Start Year 2002
Number of shared co-authors 0
Lang Li
Harbin Medical University
Career Start Year 2002
Number of shared co-authors 1
Lan Kong
Pennsylvania State University-Milton S. Hershey Medical Center
Career Start Year 2001
Number of shared co-authors 0
Heidi Spratt
University of Texas Medical Branch
Career Start Year 2001
Number of shared co-authors 3
Kerby Shedden
University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 1
Tianxi Cai
Harvard T.H. Chan School of Public Health
Career Start Year 1999
Number of shared co-authors 2
Gaurav Pandey
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Career Start Year 1999
Number of shared co-authors 0
Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Career Start Year 1999
Number of shared co-authors 3
Jeffrey S Morris
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1999
Number of shared co-authors 0
Scott M Berry
University of Kansas Medical Center
Career Start Year 1998
Number of shared co-authors 0
David Elashoff
David Geffen School of Medicine at University of California los angeles
Career Start Year 1997
Number of shared co-authors 4
Christina Rabe
Universitatsklinikum rechts der Isar, Technische Universitat Munchen
Career Start Year 1996
Number of shared co-authors 0
Atul J Butte
Bakar Computational Health Sciences Institute, University of California san francisco
Career Start Year 1993
Number of shared co-authors 1
Borko Jovanovic
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Career Start Year 1991
Number of shared co-authors 0
Rebecca A Betensky
New York University.
Career Start Year 1987
Number of shared co-authors 0
Terry M Therneau
Mayo Clinic
Career Start Year 1986
Number of shared co-authors 1
David A Schoenfeld
Mass General Hospital
Career Start Year 1977
Number of shared co-authors 3
Richard Simon
National Cancer Institute
Career Start Year 1975
Number of shared co-authors 0
Leslie M Shaw
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1968
Number of shared co-authors 1

Collaborators

Weida Tong
National Center for Toxicological Research
Co-authored papers 4
Cesare Furlanello
Bruno Kessler Foundation
Co-authored papers 4
Youping Deng
John A. Burns School of Medicine, University of Hawaii at Manoa
Co-authored papers 4
Jean Thierry-Mieg
Co-authored papers 3
Danielle Thierry-Mieg
Co-authored papers 3
Zhenqiang Su
Co-authored papers 3
Yuri Nikolsky
Co-authored papers 3
Joshua Xu
Co-authored papers 3
Matthias Fischer
University Children's Hospital of Cologne
Co-authored papers 3
Huixiao Hong
Co-authored papers 3
Charles Wang
Co-authored papers 3
Andreas Scherer
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Co-authored papers 3
Ming Shi
Co-authored papers 3
Hong Fang
National Center for Toxicological Research (NCTR)
Co-authored papers 3
Wenjun Bao
SAS Institute Inc Cary
Co-authored papers 3
Russell D Wolfinger
SAS Institute
Co-authored papers 3
Yan Li
Co-authored papers 2
Pierre R Bushel
Co-authored papers 2
Samir Lababidi
Co-authored papers 2
Marco Chierici
Fondazione Bruno Kessler
Co-authored papers 2
Marina Bessarabova
Thomson Reuters Scientific Inc.
Co-authored papers 2
Davide Albanese
Fondazione Edmund Mach
Co-authored papers 2
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 2
Jianying Li
Co-authored papers 2
Frank Berthold
Co-authored papers 2
Simon M Lin
Co-authored papers 2
Wendell D Jones
Department of Bioinformatics and Clinical Systems
Co-authored papers 2
Tieliu Shi
Co-authored papers 2
Xiaohui Fan
College of Life Sciences, Zhejiang University
Co-authored papers 2
Samantha Riccadonna
Co-authored papers 2
Release 1.2